What amazes me are the "Prevagen" ads, that are intentionally done to
look like a BP ad. Prevagen is a scam product and yet they can get away
with advertising their garbage to gullible elderly people. My fear is
that many people may see the Vascepa ads in the same light. Ask any
random person if they have ever heard of Amarin? Most will not have
a clue. Ask the same person if they ever heard of Johnson & Johnson
or Pfizer, of course they will say yes. Advertising DTC works, just
look at the Prevagen adds or the Omega-3 Larry King ads or actually
infomercials for their fish oil. In Europe they do not allow DTC
advertising, which makes AMRN's selection of a BP partner or acquirer
critical.
I can understand what AMRN is attempting to do here, that is to educate
both doctors and consumers about what works and what doesn't. My belief
is still that Vascepa must be in the hands of BP both in the US, Europe,
and the ROW for Vascepa revenues to be optimized along with having the
largest number of patients on it. A GIA strategy, if fully implemented
will not only reduce the potential return from Vascepa investors, but
the health of potential patients as well. Now,"That," would be the real
tragedy.
News 
Market Data 
Discover 
